Study S001283

Polygenic Assessment and Testing of Heterogeneity and Subtypes in Type 2 Diabetes (PATHS-T2D): A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07739537
Acronym: PATHS-T2D
Study type: INTERVENTIONAL
Phase: PHASE4
Masking: NONE
Status: NOT_YET_RECRUITING
Enrollment: 100
Start: 2026-10-01
Primary completion: 2029-09-30
Lead sponsor: Massachusetts General Hospital
Conditions: Diabete Type 2; Pharmacogenomic Drug Interaction
Interventions: DRUG:Orforglipron
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: NIH:1R01DK148455-01

Registered primary outcomes

Physiologic characterization by MMTT [1 day]
The acute drug challenges [12 days]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.